MediWound Ltd. (MDWD) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

10/25

Growth 3 Margin 1 Expansion 3 Platform 1 Financial 2

latest quarter score

Earnings Reports

10
MediWound (MDWD) Q2 2026: EscharEx Phase III Progress and NexoBrid BARDA Deal Drive Strategic Momentum
August 18, 2026
8
MediWound (MDWD) Q1 2026: BARDA Contract Adds $197M Visibility as Enrollment Pace Delays Phase III Milestone
May 27, 2026
9
MediWound (MDWD) Q4 2025: Manufacturing Capacity Grows 6x, Setting Stage for Revenue Acceleration
March 05, 2026
11
MediWound (MDWD) Q3 2025: NexoBridge Demand Drives 38% U.S. Growth, Manufacturing Expansion Sets Stage for Global Upside
November 20, 2025
9
MediWound (MDWD) Q2 2025: NexoBrid US Sales Jump 52% as Manufacturing Scale-Up Nears Completion
August 14, 2025
13
MediWound (MDWD) Q1 2025: 207% U.S. Nexobrid Revenue Surge Highlights Manufacturing Scale-Up
May 21, 2025
11
MediWound (MDWD) Q4 2024: Phase III VALUE Trial and Manufacturing Scale-Up Set Growth Trajectory
March 19, 2025

Browse all companies